French study explores genome screening for newborns
NCT ID NCT06875089
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study aims to see if it is feasible and acceptable to use genome sequencing to screen newborns for rare diseases in France. Researchers will offer the test to parents of 2,500 newborns across five hospitals, targeting treatable and actionable genetic conditions. The study will also explore why some parents decline and the emotional impact on families who receive results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could pave the way for routine genome-based newborn screening in France, enabling early detection and management of rare diseases.
- What could go wrong
- This is a small pilot study (2,500 newborns) focused on feasibility, not on proving health benefits. It may not show clear clinical utility or be accepted by all families.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWBORN SCREENING PROGRAMMES FOR RARE DISEASES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Besançon
NOT_YET_RECRUITINGBesançon, 25000, France
-
CHU Dijon Bourgogne
RECRUITINGDijon, 21000, France
-
CHU Hôtel Dieu
NOT_YET_RECRUITINGNantes, 44093, France
-
CHU Rennes - Hôpital Sud
NOT_YET_RECRUITINGRennes, 35203, France
-
CHU d'Angers
NOT_YET_RECRUITINGAngers, 49933, France